B+
Bull case
20%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
BBNX
Beta BionicsFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 demonstrated strong top-line traction, rapid PBP-channel growth, improving gross margin, and a substantial $225.2 million cash and investment balance. The type 2 pivotal trial and Mint program provide potentially meaningful long-term optionality.
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-27 · AMC.
What can break
Analyst consensus, estimate revisions, options positioning, short interest, and social coverage are incomplete or unavailable.
Momentum
37
Value
36
Sentiment
30
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $20.00 · Bear $9.50Analysis 2026-08-03; returns require an exact persisted reference.
Earnings
2026-10-27 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $24.24
Why
Momentum37 · Δ7d -36.6
Value36 · Δ7d +0.0
Sentiment30 · Δ7d -14.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-27 · AMC.
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Analyst consensus, estimate revisions, options positioning, short interest, and social coverage are incomplete or unavailable.
- • Continued substantial operating losses and negative adjusted EBITDA could require additional capital before profitability.
- • The market reaction was sharply negative after the print, while operating losses remain large and full-year revenue guidance was not raised.
Catalyst clock
2026-10-27 · AMC
Q2 growth and gross-margin improvement, but adverse post-print reaction
Lead driver: Value · See fundamentals
Momentum
37
8% active weight
Current posture
7d trendSoftening
Δ7d
-36.6
Δ21d
-58.1
Value
36
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
30
45% active weight
Current posture
7d trendSoftening
Δ7d
-14.3
Δ21d
-5.5
Why this grade
Composite grade F. Momentum 37.5 / Value 36.3 / Sentiment 30.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-03. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.03B
Beta
-
Shares Out
53.95M
P/E (TTM) · Derived
-10.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-13.82
Rev YoY
+37.8%
EPS YoY
+35.4%
Gross Margin
+58.3%
Op Margin
-69.8%
Net Debt
-$211.92M
Current Ratio
8.88
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data